基因组学视角:冒烟型多发性骨髓瘤并非独立实体
该研究对224例前驱疾病样本(含51例配对SMM与MM)及1779例新诊断MM进行二代测序分析,发现进展型SMM与配对MM的体细胞改变及克隆结构无显著差异,超过80%的驱动突变在两个时间点均存在;非进展型SMM突变负荷更低且无8号染色体拷贝数异常,基于基因组特征的评分系统可识别低危不进展患者并在101例独立样本中验证。
要点
- 进展型SMM与配对MM的基因组特征无显著差异,提示其本质接近MM。
- 非进展型SMM突变负荷更低且无8号染色体拷贝数异常,呈MGUS样特征。
- 基因组评分系统可预测低危SMM不进展,并与20/2/20联合增加临床价值。
核心结论
- 部分进展型SMM基因组上类似MM,而非进展型SMM具有MGUS样特征,SMM并非独立实体。
研究设计与样本
- 分析224例前驱疾病样本(其中51例有配对SMM和MM)及1779例新诊断MM的二代测序数据。
主要发现
- 配对样本中SMM与MM的体细胞改变和克隆结构无显著差异。
- 超过80%的驱动突变在SMM和MM两个时间点均存在。
- 超过66%的进展型样本仅显示微小克隆变化。
- 非进展型SMM浆细胞突变负荷显著更低且无8号染色体拷贝数异常。
- 基因组评分系统在101例额外独立样本中验证可识别低危不进展SMM。
关键数值与推荐
- 非进展型SMM浆细胞突变负荷显著低于进展型。
- 非进展型SMM无8号染色体拷贝数异常。
- 基因组评分系统预测低危SMM不进展,并在101例独立样本中验证。
- 基因组分类与20/2/20联合显示额外临床价值。
临床怎么用
- 对SMM患者可结合基因组特征评估进展风险,辅助识别低危不进展者。
局限性
- 结果需在更大规模研究中进一步验证,以指导未来诊断标准和试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The diagnosis of smoldering multiple myeloma (SMM) primarily relies on clinical features such as plasma cell involvement, immunoglobulin protein levels, and end-organ damage. However, as early intervention becomes a priority, the role of genomic features in differentiating risk is gaining attention. METHODS: This study analyzed next-generation sequencing data from 224 precursor condition samples with 51 patients having paired SMM and multiple myeloma (MM) and 1,779 samples from newly diagnosed MM to identify genomic features linked to progression in SMM and those with a low-risk nonprogressor precursor condition. RESULTS: Our findings from paired samples revealed no significant differences in somatic alterations and clonal structures between SMM and MM samples from the same patient. This indicates that plasma cells in progressor SMM are genomically pre-equipped with changes that define myeloma. Over 80% of driver mutations were present at both time points, and more than 66% of progressor samples showed only minor clonal changes. We further compared genomic changes between nonprogressor and progressor SMM. Nonprogressor plasma cells showed significantly lower mutational load and the absence of copy number alterations on chromosome 8. They reduced focal genomic loss compared with progressor plasma cells. A scoring system using genomic features predictively identified patients with low-risk SMM unlikely to progress, validated on 101 additional independent samples, and additive clinical value of genomic classification was further shown in combination with 20/2/20. CONCLUSION: In summary, the genomic distinctions now suggest that a proportion of SMMs with progressor phenotype are akin to MM, whereas nonprogressor SMM has monoclonal gammopathy of undetermined significance-like characteristics. The results should influence further investigation in larger studies to inform future diagnostic criteria and trial designs.
引用
- Aktas Samur A, Corre J, Talluri S, et al. Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma. J Clin Oncol. 2025. PMID: 41380103. doi:10.1200/JCO-25-00289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。